trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol dietüülfumaraat dihüdraat, glycopyrronium bromiid - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
riarify (previously chf 5993 chiesi farmaceutici s.p.a.)
chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - asendusravi keskmise või raske krooniline obstruktiivne kopsuhaigus (kok) täiskasvanud patsientidel, kes ei käsitleta piisavalt inhaleeritava kortikosteroidi ja pikatoimelise beta2-agonisti (mõju sümptomid kontrolli ja ägenemiste ennetamine vt lõik 5.
trydonis
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol dietüülfumaraat dihüdraat, glycopyrronium - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - asendusravi keskmise või raske krooniline obstruktiivne kopsuhaigus (kok) täiskasvanud patsientidel, kes ei käsitleta piisavalt inhaleeritava kortikosteroidi ja pikatoimelise beta2-agonisti (mõju sümptomid kontrolli ja ägenemiste ennetamine vt lõik 5.
fluticasone propionate gsk ninasprei, suspensioon
glaxo wellcome uk limited - flutikasoon - ninasprei, suspensioon - 50mcg 1annus 60annus 1tk
aforbe inhalatsiooniaerosool, lahus
viatris limited - formoterool+beklometasoon - inhalatsiooniaerosool, lahus - 6mcg+100mcg 1annus 120annus 2tk; 6mcg+100mcg 1annus 120annus 1tk
seffalair spiromax
teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.
foster nexthaler inhalatsioonipulber
chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsioonipulber - 6mcg+200mcg 1annus 120annus 2tk; 6mcg+200mcg 1annus 120annus 1tk
foster inhalatsiooniaerosool, lahus
chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsiooniaerosool, lahus - 6mcg+100mcg 1annus 120annus 2tk; 6mcg+100mcg 1annus 180annus 1tk
foster inhalatsiooniaerosool, lahus
chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsiooniaerosool, lahus - 6mcg+200mcg 1annus 120annus 1tk